MX2011011446A - Compuestos de sal de amonio cuaternario. - Google Patents

Compuestos de sal de amonio cuaternario.

Info

Publication number
MX2011011446A
MX2011011446A MX2011011446A MX2011011446A MX2011011446A MX 2011011446 A MX2011011446 A MX 2011011446A MX 2011011446 A MX2011011446 A MX 2011011446A MX 2011011446 A MX2011011446 A MX 2011011446A MX 2011011446 A MX2011011446 A MX 2011011446A
Authority
MX
Mexico
Prior art keywords
substituted
alkyl
quaternary ammonium
ammonium salt
salt compound
Prior art date
Application number
MX2011011446A
Other languages
English (en)
Inventor
Hiroyuki Sugiyama
Etsuko Mitsuyama
Takayuki Hara
Junji Igarashi
Satoshi Yamamura
Johji Nomura
Kei Segawa
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2011011446A publication Critical patent/MX2011011446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto representado por la fórmula (I) o una sal de mismo, que tiene una actividad agonista al receptor adrenérgico ß2 y una actividad antagonista al receptor muscarínico. R1 es H o un alquilo de C1-8. R4 es un alquileno de C1-10-. R2 es un solo enlace, un alquileno de C1-8, (sustituido) o un alquileno de C2-4, o un O-(alquileno de C1-4,), X es un enlace simple, O, CONR3, NR3CO o NR3COCH2O (en donde R3 es H o un alquilo de C1-8). A1 es un solo enlace, un arileno de C6-10 (sustituido) etc. R8 y R9 cada una es X, CN, o alquilo de C1-6, etc., a y b cada una es 0-3, W- es un anión, Y es cualquiera de las fórmulas (1) a (9), Q es cualquiera de las fórmulas (10) a (12) (en donde R6 R7 cada una es un alquilo de C1-6 (sustituido) o un fenoxialquilo de C9-10 (sustituido), n es 0-2; m es 0-3, y R5 es un alquilo de C1-6 (sustituido) (dos de R5 a R8 pueden formar una estructura en el anillo)).
MX2011011446A 2009-04-30 2010-04-27 Compuestos de sal de amonio cuaternario. MX2011011446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009110760 2009-04-30
PCT/JP2010/057422 WO2010126025A1 (ja) 2009-04-30 2010-04-27 四級アンモニウム塩化合物

Publications (1)

Publication Number Publication Date
MX2011011446A true MX2011011446A (es) 2011-11-18

Family

ID=43032170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011446A MX2011011446A (es) 2009-04-30 2010-04-27 Compuestos de sal de amonio cuaternario.

Country Status (18)

Country Link
US (1) US9072734B2 (es)
EP (1) EP2426121A4 (es)
JP (1) JP5379224B2 (es)
KR (1) KR20120061061A (es)
CN (1) CN102459231B (es)
AR (1) AR078121A1 (es)
AU (1) AU2010242646A1 (es)
BR (1) BRPI1014390A2 (es)
CA (1) CA2760630A1 (es)
HK (1) HK1166790A1 (es)
IL (1) IL216015A0 (es)
MX (1) MX2011011446A (es)
MY (1) MY155212A (es)
NZ (1) NZ595810A (es)
SG (1) SG177468A1 (es)
TW (1) TWI486343B (es)
WO (1) WO2010126025A1 (es)
ZA (1) ZA201108372B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
CN103562198B (zh) * 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
GEP20186839B (en) * 2012-12-06 2018-04-10 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
EP3134383B1 (de) * 2014-04-25 2020-04-01 Bayer CropScience Aktiengesellschaft Verfahren zum herstellen von biphenylaminen aus aniliden durch rutheniumkatalyse
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN104557589A (zh) * 2014-12-24 2015-04-29 天津大学 N-(1，1’-二芳基)取代的酰胺类衍生物的制备方法
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
WO2016180349A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
US11447485B2 (en) 2016-12-14 2022-09-20 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quanternary ammonium salt structure
CN108854841B (zh) * 2018-06-25 2020-09-29 长治学院 一种连接基含酯基的吡咯烷类手性Gemini表面活性剂及其制备方法
US11841822B2 (en) 2019-04-27 2023-12-12 Cambricon Technologies Corporation Limited Fractal calculating device and method, integrated circuit and board card
WO2020220935A1 (zh) 2019-04-27 2020-11-05 中科寒武纪科技股份有限公司 运算装置
CN111217746B (zh) * 2020-03-10 2021-09-24 佛山市隆信医药科技有限公司 一种盐酸丙卡特罗的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240784A (en) * 1966-03-15 Esters of quaternary z-hydroxy methyl piperidinium compounds
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AU2003249294A1 (en) 2002-07-17 2004-02-02 Long Y. Chiang Fullerene compounds
CN100378092C (zh) * 2003-02-14 2008-04-02 施万制药 联苯衍生物
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
CA2638788A1 (en) 2003-04-25 2004-11-11 Kos Life Sciences, Inc. Formation of strong superporous hydrogels
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
EP2492264A3 (en) * 2003-06-03 2012-12-19 Rib-X Pharmaceuticals, Inc. Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same
PE20050231A1 (es) * 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AU2007228511A1 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
ES2394547T3 (es) 2008-02-06 2013-02-01 Astrazeneca Ab Compuestos

Also Published As

Publication number Publication date
US20120046467A1 (en) 2012-02-23
US9072734B2 (en) 2015-07-07
NZ595810A (en) 2013-05-31
AR078121A1 (es) 2011-10-19
EP2426121A1 (en) 2012-03-07
MY155212A (en) 2015-09-30
KR20120061061A (ko) 2012-06-12
AU2010242646A1 (en) 2011-11-03
CN102459231B (zh) 2015-04-22
ZA201108372B (en) 2012-07-25
TW201103909A (en) 2011-02-01
SG177468A1 (en) 2012-02-28
WO2010126025A1 (ja) 2010-11-04
JPWO2010126025A1 (ja) 2012-11-01
IL216015A0 (en) 2012-01-31
BRPI1014390A2 (pt) 2016-04-05
CN102459231A (zh) 2012-05-16
EP2426121A4 (en) 2012-10-31
HK1166790A1 (en) 2012-11-09
JP5379224B2 (ja) 2013-12-25
TWI486343B (zh) 2015-06-01
CA2760630A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
MX2011011446A (es) Compuestos de sal de amonio cuaternario.
MX2012009076A (es) Composiciones de combustible.
AR087454A1 (es) Composiciones de combustible
HRP20170403T1 (hr) SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
MY160745A (en) A gasoline composition comprising one or more quaternary ammonium salt additives, and methods and uses thereto
AR085150A1 (es) Agentes moduladores de s1p
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
CO6321166A2 (es) Compuestos de pirrol
AR076412A1 (es) Compuestos diamida que tienen actividad antagonista de receptores muscarinicos y agonista del receptor adrenergico (beta)2
BR112012018865A2 (pt) naftiridinas substituídas e seu uso como inibidores de quinase syk
AR052870A1 (es) Sintesis de analogos de himbacina
HRP20191026T1 (hr) Novi derivati hidroksamične kiseline ili njihove soli
AR074511A1 (es) Proceso para la fabricacion de derivados del acido 5-metoximetilpiridin-2,3-dicarboxilico sustituido
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
RS53940B1 (en) HETEROARYL UNITS AS LIGANDS OF 5-HT4 RECEPTORS
MY160882A (en) Biocidal composition and method
RU2013145799A (ru) Новое производное октагидротиенохинолина, фармацевтическая композиция, содержащая производное, и их применение
IN2012DN03343A (es)
PE20091552A1 (es) Farmacoforos duales - antagonistas muscarinicos de pde4
MY185558A (en) Pyrido-oxazinone derivatives as tnap inhibitors
AR079104A1 (es) Compuestos organicos, proceso de preparacion y uso de los mismos
AR072031A1 (es) Compuestos de 1,1-dioxido de (1,2,4)tiadiazina
AR079697A1 (es) Bencilaminas de espiropiperidina como inhibidores de beta-triptasa
MX2022007947A (es) Derivado de amida de acido alifatico.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights